NeXT Personal Dx
Tumor-informed personalized ctDNA LDT using WGS-derived patient-specific signatures for MRD, recurrence and treatment-response monitoring.
- Developer
- Personalis
- Intended use
- Monitoring, Mrd, Recurrence Detection
- Cancer scope
- Breast cancer, Cervical cancer, Colorectal cancer, Liver cancer, Lung cancer, Melanoma
- Specimen
- FFPE tumor tissue, Plasma, Whole blood
- Molecular modality
- DNA mutation
- Current version
- Current NeXT Personal Dx clinical LDT as of 2026-09
- Evidence context
- 2 structured studies · 0 indexed performance results · 3 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.